Stock Taper 
KEY STATISTICS
COMPANY
LEADERSHIP
COMPENSATION 2026
ABOUT
PRICE TARGET
UPCOMING EARNINGS
ETFS HOLDING THIS STOCK
INSTITUTIONAL OWNERSHIP
PRICE
$78.75 ▲ UP 1.01% (+$0.79)About Kiniksa Pharmaceuticals International, plc
https://www.kiniksa.com ↗Kiniksa Pharmaceuticals, Ltd. is a Bermuda-based biopharmaceutical company developing therapies for unmet medical needs, with candidates like ARCALYST, Mavrilimumab, Vixarelimab, and KPL-404 targeting inflammatory and immune-related diseases.
INDUSTRY
A PRODUCT KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC IS KNOWN FOR
ARCALYST is the first FDA-approved weekly injectable therapy for recurrent pericarditis, blocking IL-1α and IL-1β to reduce inflammation, and is Kiniksa's leading and most commercially significant product.
Kiniksa Pharmaceuticals International in 2025
Kiniksa Pharmaceuticals Reports 61% Year-Over-Year Revenue Growth in Q3 2025, Significantly Raising Full-Year Guidance
Kiniksa Pharmaceuticals announced third-quarter 2025 financial results showing a 61% year-over-year increase in net product revenue for its flagship drug, ARCALYST, reaching $180.9 million. This strong performance led the company to significantly raise its full-year 2025 revenue guidance for ARCALYST to a range of $670-$675 million, up from the previous guidance of $625-$640 million. This event highlighted the company's successful commercial execution and solidified its transition to a profitable, cash-flow-positive biopharmaceutical company, drawing substantial positive attention from analysts and investors.
RATINGS SNAPSHOT
Overall rating: B-
MOST RECENT ANALYST GRADES
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 SYRE | $79.12 | COMPARE |
 IMVT | $30.34 | COMPARE |
 SRRK | $42.31 | COMPARE |
 ORKA | $77.76 | COMPARE |
 DNTH | $82.85 | COMPARE |
 ADPT | $27.44 | COMPARE |
 VCYT | $44.73 | COMPARE |
 IDYA | $36.63 | COMPARE |